Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2013
05/15/2013EP2592071A1 Tricyclic heterocyclic compounds
05/15/2013EP2592070A2 Tetrazole-substituted arylamides
05/15/2013EP2592066A1 Aminocarboxylic acid derivative and medical use thereof
05/15/2013EP2591806A1 Medicinal composition
05/15/2013EP2591805A1 Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
05/15/2013EP2591787A1 Combination motif immune stimulatory oligonucleotides with improved activity
05/15/2013EP2591786A1 Immunomodulating compositions and uses therefor
05/15/2013EP2591785A1 Use of 5 -androstane (alkyl)-3 ,5,6 -triol in preparing neuroprotective drugs
05/15/2013EP2591784A1 Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system
05/15/2013EP2591783A1 Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
05/15/2013EP2591782A1 Nadph oxidase 4 inhibitors and use thereof
05/15/2013EP2591781A1 Particle coating preparation
05/15/2013EP2591780A1 Topical formulations with a tertiary amine oxide
05/15/2013EP2591779A1 Topical formulations with a tertiary amine oxide
05/15/2013EP2591778A1 Polyunsaturated fatty acid compositions obtainable by a simulated moving bed chromatographic separation process
05/15/2013EP2591777A2 L-NIL as inhibitor for regenerating the lung of a patient suffering from COPD
05/15/2013EP2591776A1 Use of kukoamine a and kukoamine b
05/15/2013EP2591775A1 Combinations comprising mtor inhibitors for treating cancer
05/15/2013EP2591773A2 Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration
05/15/2013EP2591769A2 Compounds, compositions, kits and methods of use to topically treat acne and other skin conditions by administering a 19-nor containing vitamin D analog.
05/15/2013EP2591768A1 Single unit dosage formulations of sevelamer and fat soluble vitamins and surface active agents
05/15/2013EP2591675A1 Heteroaryl amide derivatives
05/15/2013EP2591354A1 Compounds and methods for inhibiting phosphate transport
05/15/2013EP2591127A1 Biotechnological production of chondroitin
05/15/2013EP2591106A1 Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
05/15/2013EP2591105A2 Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
05/15/2013EP2591104A2 Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
05/15/2013EP2591092A1 Compounds and methods for regulating integrin cd11b/cd18
05/15/2013EP2591041A1 Compositions and methods for increasing poultry hatchability and early performance
05/15/2013EP2591002A2 Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2 /kdr)
05/15/2013EP2590994A1 Vaccine against streptococcal infections based on recombinant proteins
05/15/2013EP2590987A1 Ring-fused 4 -aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases
05/15/2013EP2590985A1 Novel spiroheterocyclic compounds as mglu5 antagonists
05/15/2013EP2590984A1 Anellated pyridine compounds
05/15/2013EP2590982A1 Protein kinase inhibitors and methods of treatment
05/15/2013EP2590981A1 Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
05/15/2013EP2590980A1 Fused heterocyclic derivatives as s1p modulators
05/15/2013EP2590979A1 Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
05/15/2013EP2590978A2 Carbapenem antibacterials with gram-negative activity
05/15/2013EP2590976A1 Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
05/15/2013EP2590975A1 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
05/15/2013EP2590974A1 Tetrahydro-pyrido-pyrimidine derivatives
05/15/2013EP2590973A1 Solifenacin salts
05/15/2013EP2590972A2 Chemical compounds
05/15/2013EP2590970A1 Crystalline form of rivaroxaban dihydrate
05/15/2013EP2590969A2 Therapeutic agents 976
05/15/2013EP2590968A1 Cyclic ether compounds useful as kinase inhibitors
05/15/2013EP2590966A1 Quinazoline compounds
05/15/2013EP2590963A1 (3 -methylpyrrolidin- 3 - yl) methyl pyridinyl ether derivatives and their use as nk-3 receptor antagonists
05/15/2013EP2590961A1 Piperidinyl pyrimidine amides as kv7 potassium channel openers
05/15/2013EP2590960A1 Heterocyclic antiviral compounds
05/15/2013EP2590959A1 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders
05/15/2013EP2590957A2 Chemical compounds
05/15/2013EP2590956A1 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors
05/15/2013EP2590955A1 Spiro-cyclic amine derivatives as s1p modulators
05/15/2013EP2590954A1 Bisaryl (thio)morpholine derivatives as s1p modulators
05/15/2013EP2590953A1 Tetrazole compounds as calcium channel blockers
05/15/2013EP2590951A1 Benzenesulfonamides useful as sodium channel inhibitors
05/15/2013EP2590950A1 N-cyclyl-3 - (cyclylcarbonylaminomethyl) benzamide derivatives as rho kinase inhibitors
05/15/2013EP2590948A1 Novel quinoline esters useful for treating skin disorders
05/15/2013EP2590946A1 Bipyridyl derivatives useful for the treatment of kinase - induced diseases
05/15/2013EP2590944A1 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
05/15/2013EP2590942A1 Rho kinase inhibitors
05/15/2013EP2590941A1 Crystalline form of a 3-phenoxymethylpyrrolidine compound
05/15/2013EP2590938A1 Novel sulfonamide compounds for inhibition of metastatic tumor growth
05/15/2013EP2590937A1 Phenoxypropanol derivatives and their use in treating cardiac and cardiovascular diseases
05/15/2013EP2590936A2 Phenylcarbamate compound and muscle relaxant containing the same
05/15/2013EP2590931A1 (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
05/15/2013EP2590930A1 Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
05/15/2013EP2590929A1 Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
05/15/2013EP2590666A1 Topical application of erythropoietin for the treatment of eye disorders and injuries
05/15/2013EP2590661A1 Improved method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmaceutical active ingredients.
05/15/2013EP2590658A2 Compositions and methods for removal or destruction of amyloid fibril or amyloid adhesin comprising aggregates
05/15/2013EP2590657A1 Organic compounds
05/15/2013EP2590656A2 Compounds and methods for inhibiting phosphate transport
05/15/2013EP2590655A1 Compounds and methods for inhibiting phosphate transport
05/15/2013EP2590654A1 Combinations of kinase inhibitors for the treatment of cancer
05/15/2013EP2590653A1 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
05/15/2013EP2590652A1 Pharmaceutical compositions containing vanoxerine
05/15/2013EP2590651A1 New drug combinations for the treatment of malaria
05/15/2013EP2590650A2 Pharmaceutical compositions including carbamoyloxy arylalkanoyl arylpiperazine compound
05/15/2013EP2590648A2 Compounds for treatment of tumors bearing deregulated myc oncoproteins
05/15/2013EP2590647A2 Pro-neurogenic compounds
05/15/2013EP2590646A1 Method for inhibition of nf-kb gene expression
05/15/2013EP2590645A2 Methods for treating bipolar disorder
05/15/2013EP2590644A1 Sn-2-monoacylglycerols and lipid malabsorption
05/15/2013EP2590643A2 Multi-component pharmaceuticals for treating diabetes
05/15/2013EP2590642A2 Pkc activators and anticoagulant in regimen for treating stroke
05/15/2013EP2590641A2 Methods of immune modulation
05/15/2013EP2590640A1 Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
05/15/2013EP2590639A1 Treatment of delayed cutaneous hypersensitivity conditions with s-farnesylthiosalicylic acid and analogs thereof
05/15/2013EP2590638A1 Trans-epithelial osmotic collyrium for the treatment of keratoconus
05/15/2013EP2590637A1 Propofol for use as an antiviral medicament
05/15/2013EP2590636A1 Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
05/15/2013EP2590634A2 Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
05/15/2013EP2590631A2 Formulation for co-therapy treatment of diabetes
05/15/2013EP2590630A1 Oral dosage form of deferasirox
05/15/2013EP2590627A1 Aliskiren in form of a solid dispersion
05/15/2013EP2590624A1 Use of glabranin for stimulating hair growth
05/15/2013EP2590623A1 Malvidin for promoting hair growth
1 ... 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 ... 7860